Werner Lubitz , born in Wels, Austria, holds an MSc and a PhD in Microbiology from the Technical University of Munich, Germany. He obtained his postdoctoral training in Cell- and Tumor-Biology at the Institute of Cell Biology, University of Munich, Germany, at the Centre Hopitalier Universitaire Vaudois (CHUV) Lausanne, Switzerland, at the Wallenberg Laboratories, University of Uppsala, Sweden,at the Biocenter, University of Basel, Switzerland, and at the Max Plank Institute of Neurobiology, Martinsried, Germany, and in Genetic Engineering and Microbiology at the Institute of Microbiology,University of Victoria, Canada. Werner Lubitz was Associate Professor of Microbiology at the Institute of Microbiology, University of Kaiserslautern, Germany, and Associate Professor at the Institute of Genetics, University of Munich, Germany. Since 1987, he was Full Professor of Microbiology and Biotechnology at the University of Vienna, Austria, first at the Department of Microbiology, Genetics and Immunology, later at the Department of Medicinal Chemistry, University of Vienna, and the Center of Molecular Biology, Vienna Biocenter. He published more than 200 peer reviewed papers and holds an extensive patent portfolio. Werner Lubitz is the inventor of the Bacterial Ghost Platform Technology He is the founder and cofounder of three Biotech Companies and after retirement from the University of Vienna, 2010, he is the CEO of BIRD-C.

路演题目：Tumor Immunotherapy with Bacterial Ghost Adjuvant(BGA)